Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
CA 2429628 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Barrish, Joel; Hynes, John; Leftheris, Katerina
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods of treating one or more conditions associated with p38 kinase activity are disclosed comprising administering to a patient in need thereof at least one compound having the formula (I): or a pharmaceutically acceptable salt prodrug, or solvate thereof, wherein R3 is hydrogen methyl, perfluoromethyl, methoxy, halogen cyano, or NH2, preferably methyl, and X R1 through R6, and , Z are as described in the specification. Advantageously the groups ZR4R5 taken together comprise an NH-subsituted aryl.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 7, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 7, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 7, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.